PO.BCS01.14 · 生物信息与计算

染色质网络为人类癌症预后基因表达特征的开发提供依据

Chromatin networks inform the development of prognostic gene expression signatures in human cancers

海报缩略图:染色质网络为人类癌症预后基因表达特征的开发提供依据
编号 6877 展板 21 时间 4/22 09:00–12:00 区域 Section 3 主讲 Luigi Marchionni, MD;PhD
分会场 Network Biology and Precision Medicine
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Lucio R. Queiroz1, Shreyas Rajaram1, Karnika Singh1, Angelo Corso Faini1, Erika Minonne1, Nicola Barbaro2, Scarfó Federico3, Pushpita Roy1, Wikum Dinalankara1, Luigi Marchionni1

1Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY,2Università di Torino, Torino, Italy,3Università San Raffaele, Milano, Italy

摘要 Abstract

中文摘要
染色质结构是跨癌症类型转录调控的一个基本决定因素,然而其在生物标志物开发中的整合仍然有限。在此,我们利用DNA甲基化作为大规模三维基因组结构的替代指标,重建A/B染色质区室,并推导出捕获空间协调基因组织的染色质相互作用网络。利用这些基于甲基化的网络,我们定义了反映共享调控环境和潜在共功能行为的基因群落。我们将该框架应用于两种典型的上皮性恶性肿瘤——前列腺癌(PCa)和乳腺癌(BCa)——使用公开可用的DNA甲基化和转录组数据集,以鉴定其协调失调标志着侵袭性疾病生物学的染色质受限模块。 在两种癌症类型中,染色质驱动的基因群落与已知生物学通路的一致性均强于仅从表达数据得出的模块,凸显了将三维基因组背景纳入分子分析的价值。使用机器学习方法,我们开发了整合网络拓扑与转录改变的染色质知情预后特征,以预测转移和致死性结局。 这些特征在独立数据集中表现稳健,并持续优于仅基于表达的基线预测因子,突出了染色质背景作为关键预后信息来源的普适性。 功能分析揭示,PCa和BCa中的特征基因均富集于与肿瘤进展相关的过程,包括谱系可塑性、激素受体信号适应、染色质绝缘破坏以及区室完整性丧失。尽管具体通路以谱系特异的方式有所不同——例如PCa中的雄激素受体信号和BCa中的雌激素受体环路——但统一的机制在于促成致癌重连的高阶基因组组织的扰动。 总之,这些发现表明,源自甲基化的A/B区室结构提供了一个强大且可推广的框架,用于重建染色质网络并鉴定生物学上连贯的调控模块。通过将转录组改变嵌入其三维基因组背景中,我们推进了在多种癌症类型中具有强预后效用的染色质知情基因表达特征,此处以前列腺癌和乳腺癌为例加以说明。 披露:AI被用于协助本摘要的准备。
查看英文原文 English abstract
Chromatin architecture is a fundamental determinant of transcriptional regulation across cancer types, yet its integration into biomarker development has been limited. Here, we leverage DNA methylation as a surrogate for large-scale 3D genome structure to reconstruct A/B chromatin compartments and derive chromatin interaction networks that capture spatially coordinated gene organization. Using these methylation-informed networks, we define gene communities that reflect shared regulatory environments and potential co-functional behavior. We apply this framework to two prototypical epithelial malignancies-prostate cancer (PCa) and breast cancer (BCa)-using publicly available DNA methylation and transcriptomic datasets to identify chromatin-constrained modules whose coordinated dysregulation marks aggressive disease biology. Across both cancer types, chromatin-driven gene communities show stronger coherence with known biological pathways than modules derived solely from expression data, underscoring the value of incorporating 3D genome context into molecular profiling. Using machine-learning approaches, we develop chromatin-informed prognostic signatures that integrate network topology with transcriptional alterations to predict metastasis and lethal outcome. These signatures demonstrate robust performance across independent datasets and consistently outperform baseline expression-only predictors, highlighting the generalizability of chromatin context as a key source of prognostic information. Functional analyses reveal that signature genes in both PCa and BCa are enriched for processes implicated in tumor progression, including lineage plasticity, hormone receptor signaling adaptation, disruption of chromatin insulation, and loss of compartmental integrity. Although the specific pathways differ in lineage-specific ways-such as androgen receptor signaling in PCa and estrogen receptor circuitry in BCa-the unifying mechanism lies in perturbations of higher-order genome organization that facilitate oncogenic rewiring. Together, these findings demonstrate that methylation-derived A/B compartment structure provides a powerful and generalizable framework for reconstructing chromatin networks and identifying biologically coherent regulatory modules. By embedding transcriptomic alterations within their 3D genome context, we advance chromatin-informed gene expression signatures with strong prognostic utility across multiple cancer types, illustrated here through prostate and breast cancer. Disclosures: AI was used to assist the preparation of this abstract.
利益披露 Disclosure
L. R. Queiroz, None.. S. Rajaram, None.. K. Singh, None.. A. Corso Faini, None.. E. Minonne, None.. N. Barbaro, None.. S. Federico, None.. P. Roy, None.. W. Dinalankara, None. L. Marchionni, 10X Genomics Stock. Illumina Stock. Moderna Stock. BioNTech Stock. Pacific Biosciences Stock.

← 返回 AACR 2026 检索